Liquidia Corp (LQDA) Form 8-K — Aug 12, 2026
Liquidia reported second quarter 2026 net product sales of approximately $170.4 million for YUTREPIA (treprostinil) inhalation powder, up 31% from the first quarter of 2026, driving the company's fourth consecutive quarter of increasing profitability with net income of $74.7 million and adjusted EBITDA of $96.3 million. Since its June 2025 launch, YUTREPIA has generated approximately 5,900 unique patient prescriptions and started more than 5,000 patients on treatment through July 31, 2026, with over 1,100 prescribers and prescription-to-start conversion above 85%.
Key figures
- Eps
- $0.84 basic / $0.74 diluted
- Revenue
- $171.7 million total revenue ($170.4M net product sales + $1.3M service revenue)
- Net Income
- $74.7 million
- Revenue Yoy
- Total revenue $171.7M vs $8.8M in Q2 2025; product sales up $163.9M YoY from $6.5M
- Total Assets
- $521.9 million
- Cash Position
- $284.2 million
- Rd Expense
- $17.2 million (up 185% YoY)
- Sga Expense
- $57.4 million (up 48% YoY)
- Prescribers
- >1,100
- Adjusted EBITDA
- $96.3 million
- Cash Dec31 2025
- $190.7 million
- Cash Increase Qo Q
- $61.4 million vs Q1 2026
- Income Tax Expense
- $7.0 million
- Prior Year Net Loss
- -$41.6 million
- Rx To Start Conversion
- >85%
- Prior Year Product Sales
- $6.5 million
- Qoq Product Sales Growth
- +31%
- Clinical Studies Ongoing
- 10
- Weighted Avg Basic Shares
- 88887744
- Prescriptions Since Launch
- ~5,900
- Weighted Avg Diluted Shares
- 101397028
- Annualized Net Sales Run Rate
- ~$682 million
- Patients Treated Since Launch
- >5,000
Price after filing
Close on the filing date to close N calendar days later (from $91.03). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.